The maximum institutional overhead payment is 5% of the award (i.e., $1,000 for a $20,000 award). Overhead payments are included within the award itself and not paid out in addition to the award.

•    Research involving active and/or placebo controls will have these costs included in the budget.
•    Once a grant has been provided, no further funding may be added at a later date.

Authorized expenses may include goods and materials necessary to complete the research project, costs associated with the publication of the research, staff salaries, etc. This is a non-exhaustive list. If in doubt about which expenses are authorized, please contact the program administrator at REACHAwards@porterhousemedical.com.

The following expenses are not permitted within the budget:
⦁    Salaries, travel, and/or housing related to sabbaticals
⦁    Purchase or rental of office equipment
⦁    Fees for tuition
⦁    Membership dues, subscriptions, books, or journals

Projects will receive a percentage of the funding upfront (after all required documents have been received) and then per agreed-upon milestones (following receipt of satisfactory progress reports and/or final reports).

More than one application from the same institution (university, hospital, center) is permitted. Multiple applications from researchers at such an institute collaborating on one project are not permitted.

If there are any significant changes in an award recipient’s circumstances, the award recipient must contact the program administrator to describe these changes and explain how they might affect the use of the awarded funds.

Awards are issued to the award recipient and the institution with which he/she is affiliated. Thus, the program administrator must be notified of any changes in institutional affiliation. The transfer of a grant to another institution or investigator will be at the sole discretion of the program administrator.

For all awards, progress and financial reports must be submitted to the program administrator at 6 months. Final reports are due 60 days after the end of the funding period. Progress and Financial report templates will be e-mailed to awardees at least one month before the deadline.

The program reserves the right to terminate support of a funded project at any time for any cause.

For-profit organizations are not allowed to apply to the REACH Awards, e.g., pharmaceutical companies, homecare companies, health maintenance organizations, etc. The exceptions are research laboratories and academic institutions that may exist as part of a hospital that is run for profit. If you are in doubt about eligibility, please contact the program administrator.

As a condition for funding, Bayer may ask for right of first refusal to obtain an exclusive worldwide license to any technology invented or improved under the grant. This intellectual property includes, but is not limited to, patented inventions, technical data, materials, and know-how. It does not include any technology invented prior to the award period, after the end of the award period, or to technology invented by the investigators during the period of funding but not supported in any way by this award.

Bayer recognizes that its conditions may prove prohibitive for certain institutions with conflicting intellectual property policies in place, and is consequently open to alternate arrangements if necessary. Such arrangements, however, should be aligned with the REACH Awards’ objective of treating, to the greatest extent possible, all award recipients in a substantially identical manner.

Applicants requesting an award to carry out research with recombinant molecules and/or animal or human subjects must obtain approval from the appropriate institutional or government authorities, e.g., an Institutional Review Board. 

If an applicant’s institution does not require special permission for using recombinant molecules, then this must be communicated to the program administrator. The program administrator must receive copies of appropriate permissions before any award funds are disbursed.

The applicant’s institution has responsibility for ensuring that the rights of any human subjects are upheld and that animals are cared for in a humane manner.

The REACH Awards encourage award recipients to publish work carried out under this award, including abstract submissions to congresses. Award recipients must acknowledge the receipt of funding from the REACH Awards in publications and abstracts when describing research conducted with awards received from the REACH Awards.
Non-human and clinical studies should be submitted to a peer-reviewed journal within one year of completion.

When clinical trials are required for clinical investigations, the project must meet the standards for good clinical practice and must conform to all local safety reporting regulations. If research involves human subjects, the study must be linked on ClinicalTrials.gov and should be submitted to a peer-reviewed journal within one year of completion.

Patient safety is the primary concern in any clinical study. Thus, Bayer will not release funds for the clinical trial until both Bayer and the investigators agree on the safety and suitability of the trial. In addition, relevant patient safety data must be supplied to the appropriate Bayer safety officer.